Eloxx Pharmaceuticals, Inc.
ELOX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001035354
No open-market purchases or sales by Eloxx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $34.7M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Eloxx Pharmaceuticals, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 0 | 22 | +22 |
| Shares | 0 | 2.50M | +2.50M |
| Value | $0 | $34.7M | +$34.7M |
New holders (22)
Institutions that held Eloxx Pharmaceuticals, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nantahala Capital Management, LLC | 400,000 | $5.55M | 0.34% |
| EcoR1 Capital, LLC | 400,000 | $5.55M | 0.28% |
| Standard Life Aberdeen plc | 400,000 | $5.55M | 0.01% |
| Samsara BioCapital, LLC | 400,000 | $5.55M | 0.46% |
| Siren, L.L.C. | 400,000 | $5.55M | 0.11% |
| Stonepine Capital Management, LLC | 397,160 | $5.51M | 4.20% |
| Vanguard Capital Management LLC | 78,680 | $1.09M | 0.00% |
| Vanguard Fiduciary Trust Co | 10,602 | $147.2K | 0.00% |
| Seven Grand Managers, LLC | 10,000 | $138.8K | 0.01% |
| Morgan Stanley | 1,544 | $21.4K | 0.00% |
| Vanguard Global Advisers, LLC | 718 | $9.97K | 0.00% |
| UBS Group AG | 637 | $8.84K | 0.00% |
| Wells Fargo & Company | 126 | $1.75K | 0.00% |
| Pioneer Family Office, LLC | 96 | $1.33K | 0.00% |
| Royal Bank of Canada | 98 | $1.00K | 0.00% |
| Altshuler Shaham Ltd | 25 | $347 | 0.00% |
| Barclays PLC | 12 | $167 | 0.00% |
| Old Point Trust & Financial Services N A | 5 | $69 | 0.00% |
| Citigroup Inc | 4 | $56 | 0.00% |
| Activest Wealth Management | 4 | $56 | 0.00% |
| SBI Securities Co., Ltd. | 2 | $28 | 0.00% |
| Point Nemo Capital, LLC | 1 | $14 | 0.00% |
Sold out (0)
Institutions that held Eloxx Pharmaceuticals, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
None.